CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0186-000 |
|---|---|
| Brand Name | Cabometyx |
| Generic Name | Cabozantinib |
| Strength | 20 mg, 40 mg & 60 mg |
| Tumour Type | Gastrointestinal |
| Indication | Hepatocellular Carcinoma |
| Funding Request | For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Review Status | Complete |
| Pre Noc Submission | Yes |
| NOC Date | November 8, 2019 |
| Manufacturer | Ipsen Biopharmaceuticals Canada Inc. |
| Sponsor | Ipsen Biopharmaceuticals Canada Inc. |
| Submission Date | October 16, 2019 |
| Submission Deemed Complete | October 30, 2019 |
| Submission Type | Initial |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | October 30, 2019 |
| Check-point meeting | January 8, 2020 |
| pERC Meeting | March 19, 2020 |
| Initial Recommendation Issued | April 2, 2020 |
| Feedback Deadline ‡ | April 17, 2020 |
| Final Recommendation Issued | April 22, 2020 |
| Notification to Implement Issued | May 7, 2020 |
| Therapeutic Area | HCC |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
